Factor X, also known by the eponym Stuart-Prower factor or as prothrombinase, thrombokinase or thromboplastin, is an enzyme (EC 3.4.21.6) of the coagulation cascade. It is a serine endopeptidase (protease group S1). The first crystal structure of human factor X a was deposited in May 1993. Till now, 191 crystal structures of factor X a with various inhibitors have been deposited in the protein data bank. The active site of factor X a is divided into four sub pockets as S1, S2, S3 and S4 [1] (Figures 1-3) .
Rivaroxaban (BAY 59-7939) is an oral anticoagulant invented and manufactured by Bayer. It is the first available orally active direct factor X a inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor X a occurs four hours after a dose. The effects last approximately 8-12 hours, but factor X a activity does not return to normal within 24 hours so once-daily dosing is possible. is an oxazolidinone derivative optimized for inhibiting both free Factor X a and Factor X a bound in the prothrombinase complex. It is a highly selective direct Factor X a inhibitor with oral bioavailability and rapid onset of action. Inhibition of Factor X a interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi [3] .
Rivaroxaban does not inhibit thrombin (activated Factor II), and no effects on platelets have been demonstrated. Rivaroxaban has predictable pharmacokinetics across a wide spectrum of patients (age, gender, weight, race) and has a flat dose response across an eightfold dose range (5-40 mg) [3] . Rivaroxaban bears a striking structural similarity to the antibiotic linezolid ((S)-N-({3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide): both drugs share the same oxazolidinone-derived core structure. Accordingly, rivaroxaban was studied for any possible antimicrobial effects and for the possibility
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Apixaban (BMS-562247-01) is an anticoagulant for the treatment of venous thromboembolic events. It is a direct factor X a inhibitor. [5,4-c] pyridine-3-carboxamide) has been available in Europe since May 2012. In the United States, it is undergoing phase III trials for the prevention of venous thromboembolism. It is being developed in a joint venture by Pfizer and Bristol-Myers Squibb. Apixaban is a highly selective; orally bioavailable and reversible direct inhibitor of free and clot-bound factor X a . Factor X a catalyzes the conversion of prothrombin to thrombin, the final enzyme in the coagulation cascade that is responsible for fibrin clot formation. Apixaban has no direct effect on platelet aggregation, but by inhibiting factor X a , it indirectly decreases platelet formation induced by thrombin [5] .
Edoxaban (DU-176b) is an anticoagulant drug which acts as a direct factor X a inhibitor. Edoxaban (N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H- [1, 3] thiazolo [5,4-c] pyridine-2-carbonyl)amino]cyclohexyl] oxamide) is being developed by Daiichi Sankyo. It was approved in July for the prevention of stroke and non-central-nervous-system systemic embolism. Several Phase II clinical trials have been conducted, for example for thromboprophylaxis after total hip replacement (phase III early results compare well to enoxaparin and for stroke prevention in patients with atrial fibrillation (phase III has completed enrollment [6] . A large phase III trial (ENGAGE AF-TIMI) showed that edoxaban was non inferior to warfarin in preventing recurrent venous thromboembolic events with fewer episodes of major bleeding. This paper follows similar recent major trials showing similar results for the other new factor X a inhibitors, rivaroxaban and apixaban [7] .
Betrixaban (PRT-054,021) is an anticoagulant drug which acts as a direct factor X a inhibitor. It is potent, orally active and highly selective for factor X a , being selected from a group of similar compounds for its low hERG affinity. Betrixaban (N-(5-chloropyridin-2-yl)-2-([4-(N,Ndimethylcarbamimidoyl)benzoyl]amino)-5-methoxybenzamide) has undergone human clinical trials for prevention of embolism after knee surgery and prevention of stroke following atrial fibrillation, with promising results. Joint development with Portola was discontinued in 2011 by Merck [7] . Darexaban (YM150) is a direct inhibitor of factor X a created by Astellas Pharma. It is an experimental drug that acts as an anticoagulant and antithrombotic to prevent venous thromboembolism after a major orthopaedic surgery, stroke in patients with atrial fibrillation and possibly ischemic events in acute coronary syndrome. It is used in form of the maleate [8] . Factor X a (FX a ) is an essential blood coagulation factor that is responsible for the initiation of the coagulation cascade. FX a cleaves prothrombin to its active form thrombin, which then acts to convert soluble fibrinogen to insoluble fibrin and to activate platelets. Stabilization of the platelet aggregation by fibrin mesh ultimately leads to clot formation. Darexaban (N-(3-Hydroxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl)-4-methoxybenzamide) and darexaban glucuronide selectively and competitively inhibit FXa, suppressing prothrombin activity at the sites of blood clot (thrombus) formation. This leads to a decrease in blood clot formation in a dose dependent manner. Reducing blood clot formation will decrease blood flow blockages, thus possibly lowering the risk of myocardial infarction, unstable angina, venous thrombosis, and ischemic stroke. Atrial fibrillation is an abnormal heart rhythm that causes a reduction in the cardiac output and blood flow to the brain. It also promotes the formation of blood clots in the atria. Atrial fibrillation is associated with an increased risk of embolic stroke due to the increased risk of blood clot development. Oral anticoagulant drugs such as Darexaban decrease the incidence and severity of stroke in patients with atrial fibrillation by preventing the formation of blood clots [9] .
is an experimental injectable anticoagulant direct factor X a inhibitor that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial [10] .
Conclusion
The oral direct factor X a inhibitors include rivaroxaban and apixaban that recently have been evaluated comprehensively in multiple randomized clinical trials. Based on the efficacy and safety data from these trials, these novel anticoagulants are disseminating throughout clinical practice for thromboprophylaxis in major lowerextremity joint replacement, acute medical illness, atrial fibrillation and acute coronary syndromes. The advantages of the xabans over vitamin K antagonists include no requirement for routine anticoagulation monitoring as well as a fast and reliable onset of action. The first preoperative limitation of the xabans is the lack of a routine coagulation test for monitoring their anticoagulant effect in scenarios, such as the timing of surgical procedures, the reversal of xaban-related bleeding and the conduct of regional anesthesia. A second preoperative limitation is the lack of fully validated clinical reversal agents although prothrombin complex concentrate, recombinant factor VIIa and factor X concentrate are options for xaban reversal in life-threatening bleeding scenarios. Given their clinical efficacy and advantages, further xabans are in clinical development, with edoxaban already in phase III clinical trials. Although the xabans have ushered in a new paradigm for clinical anticoagulation, further clinical trials are indicated to refine their clinical indications even further, such as anticoagulation for patients with mechanical heart valves.
